These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29288595)

  • 1. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis.
    McDonald SA; Innes HA; Aspinall EJ; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    Liver Int; 2018 Aug; 38(8):1402-1410. PubMed ID: 29288595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study.
    McDonald SA; Hutchinson SJ; Bird SM; Mills PR; Robertson C; Dillon JF; Williams T; Goldberg DJ
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):49-57. PubMed ID: 19773667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
    Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.
    Rodríguez-Tajes S; Pocurull A; Castillo J; Casanova G; Vega L; Lens S; Mariño Z; Londoño MC; Forner A; Torres F; Forns X
    J Hepatol; 2020 Dec; 73(6):1360-1367. PubMed ID: 32697948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    McDonald SA; Barclay ST; Innes HA; Fraser A; Hayes PC; Bathgate A; Dillon JF; Went A; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2021 Sep; 28(9):1246-1255. PubMed ID: 34002914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
    McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
    J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems.
    Tsui JI; Pletcher MJ; Vittinghoff E; Seal K; Gonzales R
    J Hepatol; 2006 Feb; 44(2):262-6. PubMed ID: 16226823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
    Zou B; Yeo YH; Jeong D; Park H; Sheen E; Lee DH; Henry L; Garcia G; Ingelsson E; Cheung R; Nguyen MH
    Dig Dis Sci; 2020 May; 65(5):1520-1528. PubMed ID: 31598919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and economic burden of viral hepatitis: an observational population based study.
    Steinke DT; Weston TL; Morris AD; MacDonald TM; Dillon JF
    Gut; 2002 Jan; 50(1):100-5. PubMed ID: 11772975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies.
    Ibáñez Samaniego L; Pérez Valderas M; Fernández Yunquera A; Rincón Rodríguez D; López Baena JA; Matilla Peña A; Catalina Rodríguez MV; Clemente Ricote G; Bañares Cañizares R; Salcedo Plaza M
    Transplant Proc; 2014 Nov; 46(9):3084-6. PubMed ID: 25420829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C.
    Cholankeril G; Perumpail RB; Hu M; Skowron G; Younossi ZM; Ahmed A
    Dig Dis Sci; 2016 Sep; 61(9):2505-15. PubMed ID: 27084385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing Economic Burden in Hospitalized Patients With Cirrhosis: Analysis of a National Database.
    Desai AP; Mohan P; Nokes B; Sheth D; Knapp S; Boustani M; Chalasani N; Fallon MB; Calhoun EA
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00062. PubMed ID: 31343469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.
    Younossi ZM; Otgonsuren M; Henry L; Arsalla Z; Stepnaova M; Mishra A; Venkatesan C; Hunt S
    J Viral Hepat; 2015 Feb; 22(2):137-45. PubMed ID: 24813350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension.
    Nguyen GC; Segev DL; Thuluvath PJ
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1092-9. PubMed ID: 17625983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis.
    Adejumo AC; Adegbala OM; Adejumo KL; Bukong TN
    Can J Gastroenterol Hepatol; 2018; 2018():9430953. PubMed ID: 30345261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    Wang H; Swann R; Thomas E; Innes HA; Valerio H; Hayes PC; Allen S; Barclay ST; Wilks D; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Gunson R; Mclntyre PG; Hunt A; Hutchinson SJ; Mills PR; Dillon JF
    J Viral Hepat; 2018 Aug; 25(8):930-938. PubMed ID: 29577515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.